Baseline PLT strata of 50-150 × 109/L, >150-300 × 109/L and >300 × 109/L in addition to the
overall intent-to-treat (ITT) population were examined for S1. At week 24, MMB treatment
elicited a TI response rate of 62%-72% in each baseline PLT stratum and 67% in the ITT. In
comparison, TI rates were 42%-54% in RUX PLT strata vs 49% in the ITT. The splenic response
rate (SRR) was maintained at 19%-35% in all PLT strata on MMB vs 27% in the ITT, whereas a
marked reduction in SRR was observed with lower baseline PLTs on RUX; 4% SRR for PLTs 50-
150 × 109/L vs 29% in the ITT. On MMB the TSS response rate was within the range of 23%-
33% in the various PLT strata and 28% for the ITT, compared with 33%-46% in RUX PLT strata
and 41% in the ITT.
In S2, response rates in the MMB arm for all three response parameters remained very
consistent between the ITT and the PLTs ≤150 × 109/L stratum. Symptomatic and anemia
benefits were also preserved for PLTs ≤50 and >50-100 × 109/L. Response rates in the BAT arm
were low.
Rates of treatment-emergent adverse events on MMB were generally similar between the
overall safety population and for PLTs <150 × 109/L. However, in S1, nausea, fatigue and
anemia were more common with PLTs <150 × 109/L vs overall (21-23% vs 15-16%).
These analyses demonstrate that MMB’s safety and activity do not appear to be affected by
baseline PLT count. In contrast, activity with RUX was reduced in patients with lower baseline
PLT counts impacting the clinical utility of the compound in these patients. Therefore, the
relative benefit-risk profile of MMB is generally comparable or favorable to that of RUX in JAKi-naïve
patients whose PLT count is ≤300 × 109/L. These analyses complement previous findings
highlighting the ability to initiate and maintain near-maximal MMB dose intensity irrespective
of baseline PLTs, suggesting that durable dosing contributes to the compound’s efficacy
profile.
SCIENTIFIC PROGRAMME
SESSION I
OPTIMIZING
CYTOREDUCTION
SESSION II
MANAGEMENT OF CML
WITH TKI
SESSION III
MPN RISK
STRATIFICATION
INCLUDING VASCULAR
EVENTS
DEBATE 1
INTERFERON ALPHA
SHOULD BE FRONT LINE
THERAPY IN ALL ET/PV
PATIENTS
ROUNDTABLE 1
INFECTIONS IN
MYELOPROLIFERATIVE
DISORDERS, INCLUDING
CML
ROUNDTABLE 2
PREGNANCY AND
PARENTING
DEBATE 2
ALLOGENEIC STEM CELL
TRANSPLANTATION
SHOULD BE CONSIDERED
THIRD LINE OPTION IN
CHRONIC PHASE CML
SESSION IV
EVOLVING THERAPIES
IN MYELOFIBROSIS
SESSION V
MANAGEMENT OF
ADVANCED AND UNUSUAL
DISEASE (MPN AND CML)
SESSION VI
TREATMENT FREE
REMISSION IN CML
KEYNOTE LECTURE
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FO R A POSTER
PRESENTATION
DISCLOSURES